Company intelligence / Profile preview
Vandria SA
Lausanne/Epalinges, Vaud, Switzerlandvandria.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Vandria has dosed the first subjects in a Phase 1 clinical trial of VNA‑318, an orally available small molecule mitophagy inducer targeting CNS disorders. Preclinical data show improved memory/cognition and disease-modifying effects in models of Alzheimer’s/Parkinson’s. The company holds composition-of-matter patents on its lead series.
- Therapeutic areas
- GastroenterologyMetabolic DisordersImmunologyEndocrinologyOncologyRare DiseasesNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Open to partnering with biotech/pharma companies for both the mitophagy pipeline and ferroptosis inhibitors; no major partnerships announced yet as of June 2025.
Beyond the preview
Go deeper on Vandria SA.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vandria SA.